Hepatic: Serum bilirubin \< 2.0 mg/dL; AST and ALT \< 2 x ULN w/o liver metastases or \<5 x ULN w/liver metastases
Renal: Creatinine \< 2.0 mg/dL
Cardiovascular: Patients with LVEF \>/= 50% by MUGA or 2D-ECHO.
Pulmonary: Patients with DFCO and FEV1 \>/= 60% by required Pulmonary Function Tests.
Other: Patients agreeing to use a medically effective method of contraception while enrolled in the study. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent.
You may not be if
Patients with at least one measurable tumor site \> 1.5 cm in at least one dimension.
Prior/Concurrent Therapy:
Biologic Therapy: Patients who have received human or humanized monoclonal antibodies will be eligible provided pre-study evaluations demonstrate no significant reactivity with hLL2 IgG (i.e., HAHA).
